TB Drug Research & Development Activity Survey

What is the Stop TB Partnership Working Group on New Drugs?

One of the Stop TB Partnership's seven Working Groups, the Working Group on New Drugs (WGND) is a network of expert individuals committed to accelerating the development of effective and affordable new therapies for TB. The WGND acts as a forum to facilitate global collaborations for the development of new TB drugs and promotes coordination of all stakeholders in this process. For further information, or to join the Group, please visit the WGND website at: http://www.stoptb.org/wg/new_drugs/.

What is the Purpose and Product of This Survey?

A robust and sustained pipeline of TB drug candidates and discovery programs is essential to successful development of new TB drug regimens. TB must be treated with a combination of drugs, thus prospective new drugs must be evaluated for compatibility and complementarity. With the aim of increasing efficiency and coordination of the global TB drug R&D enterprise through information-exchange, the WGND conducts an annual survey of worldwide TB drug R&D activities. This exercise also identifies critical gaps in resources and capacity.

Product – Changes for 2008
In 2006 and 2007 the WGND published information gathered as a chart on their website at: http://www.stoptb.org/wg/new_drugs/projects.asp. For 2008, in addition to a chart of activities, full information submitted on each project will be published as a booklet on website.

Information sought – Changes for 2008
For the purpose of this particular survey, the WGND is interested in gathering information on clinical and preclinical development programs in progress as well as ongoing drug discovery projects (at the high throughput screening, hit to lead or lead optimization stage). Please include projects that address new indications for existing drugs or chemical optimization/ reformulation of currently available drugs. Information on basic research will be sought via a separate survey.